Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Dual/triple agonist, GLP-1RA, Topics

Novo Initiates Metsera Bidding War  

Here is a brief preview of this blast: Novo Nordisk announced it submitted an unsolicited proposal to acquire Metsera in a deal valued up to $9.0B. Recall, last month, Pfizer announced it entered into a definitive merger agreement to acquire the New York-based biotech in a deal valued up to $7.3B (previous FENIX insight). Following the news, Metsera’s stock price soared ~23% to $64/share. Below, FENIX provides insight into the Metsera bidding war, including thoughts on Novo as a strategic fit, Pfizer’s potential response, and readthrough to other acquisition targets. FENIX’s bold prediction: Pfizer will ultimately win and acquire Metsera.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.